Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis

Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis

Background: Sorafenib (Sor) represents a first-line therapy for hepatocellular carcinoma (HCC); however, its efficacy is constrained by secondary failure, which limits its clinical use. Recent studies have indicated that the suppression of Programmed cell death-Ligand 1 (PD-L1) may potentiate Sor�...

Full description

Bibliographic Details
Main Authors: Junfei Li, Chenghui Zhu, Zengyu Zhang, Xiaorong Zheng, Chunlei Wang, Hongyan Zhang
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Heliyon
Subjects:
Sorafenib
Hepatocellular carcinoma
NF-κB
PD-L1
Paeoniflorin
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024004924

Similar Items

Similar Items